Skip to main content

Nobel Prize

Nobel Prize goes to microRNA researchers



Victor Ambros (l) and Gary Ruvkun (r) share the 2024 Nobel Prize in Physiology or Medicine

The Nobel Prize in Physiology or Medicine 2024 has been awarded to US scientists Victor Ambros and Gary Ruvkun for their work on microRNA. Their discoveries help explain how complex life emerged on Earth and how the human body is made up of a wide variety of different tissues. MicroRNAs influence how genes - the instructions for life - are controlled inside organisms, including us. The winners share a prize fund worth 11m Swedish kronor (£810,000).

Every cell in the human body contains the same raw genetic information, locked in our DNA. However, despite starting with the identical genetic information, the cells of the human body are wildly different in form and function.

The electrical impulses of nerve cells are distinct from the rhythmic beating of heart cells. The metabolic powerhouse that is a liver cell is distinct to a kidney cell, which filters urea out of the blood. The light-sensing abilities of cells in the retina are different in skillset to white blood cells that produce antibodies to fight infection.

So much variety can arise from the same starting material because of gene expression. The US scientists were the first to discover microRNAs and how they exerted control on how genes are expressed differently in different tissues. The medicine and physiology prize winners are selected by the Nobel Assembly of Sweden's Karolinska Institute. They said: “Their groundbreaking discovery revealed a completely new principle of gene regulation that turned out to be essential for multicellular organisms, including humans.

"It is now known that the human genome codes for over 1,000 microRNAs.” Without the ability to control gene expression, every cell in an organism would be identical, so microRNAs helped enable the evolution of complex life forms.

Abnormal regulation by microRNAs can contribute to cancer and to some conditions, including congenital hearing loss and bone disorders. A severe example is DICER1 syndrome, which leads to cancer in a variety of tissues, and is caused by mutations that affect microRNAs.


Prof Ambros, 70, works at the University of Massachusetts Medical School, and Prof Ruvkun, 72, is a professor at Harvard Medical School. Both conducted their research on the nematode worm - C. elegans. They experimented on a mutant form of the worm that failed to develop some cell types, and eventually homed in on tiny pieces of genetic material or microRNAs that were essential for the worms' development.

This is how it works:A gene or genetic instruction is contained within our DNA. Our cells make a copy, which is called messenger RNA or simply mRNA (you'll remember this from Covid vaccines). This travels out of the cell's nucleus and instructs the cell's protein-making factories to start making a specific protein. But microRNAs get in the way by sticking to the messenger RNA and stop it working. In essence the mircoRNA has prevented the gene from being expressed in the cell

Further work showed this was not a process unique to worms, but was a core component of life on Earth. Prof Janosch Heller, from Dublin City University, said he was "delighted" to hear the prize had gone to Profs Ambros and Ruvkun.

"Their pioneering work into gene regulation by microRNAs paved the way for groundbreaking research into novel therapies for devastating diseases such as epilepsy, but also opened our eyes to the wonderful machinery that is tightly controlling what is happening in our cells.”
microRNA, gene regulation, non-coding RNA, post-transcriptional control, RNA interference, miRNA biogenesis, miRNA target prediction, miRNA biomarkers, oncogenic miRNAs, tumor suppressor miRNAs, circulating miRNAs, exosomal miRNAs, miRNA therapeutics, miRNA-based diagnostics, next-generation sequencing, RNA sequencing, miRNA expression profiling, epigenetic regulation, small RNA, precision medicine

#microRNA #miRNA #GeneRegulation #NonCodingRNA #RNAi #miRNABiogenesis #miRNATarget #miRNABiomarkers #OncoMiRs #TumorSuppressorMiRNAs #CirculatingMiRNAs #ExosomalMiRNAs #miRNATherapeutics #miRNADiagnostics #RNASequencing #NGS #miRNAExpression #Epigenetics #SmallRNA #PrecisionMedicine

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetic Test

Genetic test eliminates progressive retinal atrophy in English shepherd dogs Researchers at the University of Cambridge recently published their findings in Genes after identifying the genetic mutation that is causing progressive retinal atrophy (PRA) in English shepherd dogs. PRA is a group of inherited diseases causing progressive degeneration of the light sensitive cells within the back of the eyes. When it comes to PRA in dogs, they are born with normal vision but by the age of 4-5 they go totally blind with no treatment. According to the release, by identifying the canines carrying this disease before they lose vision, this can be then used as a tool to guide breeding decisions to prevent the passing of the disease onto puppies.1 Historically, owners did not realize their dog had PRA until they were middle-aged, which means it could have been passed on to puppies if they had bred, making this a hard disease to control. “Once the dog’s eyesight starts to fail there’s no treatment ...
Post a Comment
Read more